EMA suspends, recalls AbbVie and Biogen's doomed MS drug Zinbryta

European regulators announced on Friday that they were "urgently reviewing" Zinbryta on safety concerns. (CC0 Public Domain)

Less than a week after announcing that they were “urgently reviewing” AbbVie and Biogen multiple sclerosis drug Zinbryta on safety concerns, European regulators are recommending an immediate suspension and recall of the product.

The European Medicines Agency announced the move on Wednesday, citing 12 reports of serious inflammatory brain disorders worldwide, including encephalitis and meningoencephalitis. Three of those cases led to patient deaths, the agency noted.

And that’s not all. “Zinbryta may also be linked to severe immune reactions affecting several other organs,” the body warned.

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

THIS WEEK: Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today!

The suspension and recall follow AbbVie and Biogen’s decision to yank the drug from markets around the globe. The pair made the call on Friday, the same day the EMA unveiled its review.

RELATED: Biogen, AbbVie yank underperforming MS drug Zinbryta after encephalitis reports

Friday wasn’t the first time Zinbryta had stirred up safety concerns, though. In the U.S., the drug carried a black-box warning against use in patients with liver problems, and in Europe, regulators had placed limits on its use and required strict liver monitoring.

RELATED: Biogen, AbbVie hit with Zinbryta safety action in EU as MS market heats up

For now, the EMA advised, doctors should contact their Zinbryta patients immediately to stop their treatment and look for an alternative therapy. Once stopping therapy, patients should be followed up with for at least 6 months, it said.

Suggested Articles

The new Community trial will first test Amgen's Otezla, Takeda's Takhzyro and UCB's zilucoplan in hospitalized patients.

Indivior faces a new lawsuit from RB, its former parent company, over a scheme to market opioid addiction therapy Suboxone Film.

A new FDA effort brings cancer drug labels to life in videotaped panels with experts, debuting its first episode on Seagen's MBC med Tukysa.